Conference PPT (5 MB) - Institute for Oral Health
Conference PPT (5 MB) - Institute for Oral Health
Conference PPT (5 MB) - Institute for Oral Health
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Risk of Osteonecrosis of the Jaw <strong>for</strong><br />
Patients Taking Bisphosphonates<br />
• Risk <strong>for</strong> developing ONJ with IV bisphosphonates<br />
is ~10-12% 12% (multiple myeloma, breast CA-any CA<br />
metastatic to bone; drugs control osteoclasts).<br />
• Risk <strong>for</strong> developing ONJ with oral bisphosphonates<br />
is less than 1%.<br />
• Lower risk <strong>for</strong> ONJ in first 6 months of IV therapy;<br />
first 3 years of oral treatment.<br />
Source: Migliorati, CA, JA Casiglis, J. Epstein, PI Jacobsen, MA Siegel, SB Woo.<br />
Managing the care of patents with bisphospnhonate-associated associated osteonecrosis:<br />
An American Academy of <strong>Oral</strong> Medicine position paper. JADA 136(12):1658<br />
):1658-68, 68,<br />
2005.
Change language